May 03, 2016

Lilienfeld, Polovoy and Kessel Weigh in on Delaware Director Compensation Cases

配信申込

ジャンプリンクテキスト

 
To successfully defend legal challenges against compensation committee decisions, biopharmaceutical companies must make greater efforts to obtain the necessary approvals from stockholders.  Healthcare industry partners Doreen Lilienfeld, Brian Polovoy and Mark Kessel co-authored a letter to the editor on this subject that was published in Nature Biotechnology. According to the authors, biopharmaceutical companies will ignore the Delaware director compensation cases at their own peril.

View full article, Delaware Director Compensation Cases

著者等

Doreen E. Lilienfeld

パートナー

報酬・ガバナンス・従業員退職所得保証法(ERISA)

+1 212 848 7171

+1 212 848 7171

+1 650 838 3804

+1 650 838 3804

ニューヨーク